Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
BMC Public Health|December 6, 2025
The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based studyIbrahim Diakite, Keisuke Tobe, Xuedan You, et al.
Expert Review of Vaccines|October 22, 2024
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in JapanAkiko Mizukami, Victor Preckler, Frederik Verelst, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 3, 2004
Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient miceKikuo Isoda, Shojiro Sawada, Norio Ishigami, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitisYutaka Komiyama, Susumu Nakae, Taizo Matsuki, et al.
Circulation|September 1, 2005
Involvement of tumor necrosis factor-alpha in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient miceTaizo Matsuki, Kikuo Isoda, Reiko Horai, et al.
Clinical Drug Investigation|November 1, 2017
Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort StudyAkiko Mizukami, Keiko Sato, Koichi Adachi, et al.
Dermatology and Therapy|June 6, 2022
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older AdultsLida Teng, Akiko Mizukami, Cheryl Ng, et al.
Expert Review of Vaccines|March 1, 2024
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysisDaisuke Kurai, Akiko Mizukami, Victor Preckler, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 13, 2026
Estimating respiratory syncytial virus health utility values for older adults and their caregivers in the Japanese population: a time trade-off studyRegina Rendas-Baum, Jakob Bjorner, Victor Preckler, et al.
Journal of Medical Economics|December 20, 2024
Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approachPeter P Mueller, Atsushi Tajima, Kelsie Cassell, et al.
Pageof 4